Showing 1381-1390 of 1555 results for "".
- Johnson & Johnson to Showcase Tecnis Odyssey IOL and Present New Research at AAO 2024https://modernod.com/news/johnson-johnson-to-showcase-tecnis-odyssey-iol-and-present-new-research-at-aao-2024/2482501/Johnson & Johnson will highlight its latest innovations in eye health during the 2024 American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21 in Chicago. Among the company's spotlight advancements is the Tecnis Odyssey IOL, a new presbyopia-correcting IOL t
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- J&J Expands Availability of Tecnis Odyssey PC-IOLhttps://modernod.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- Scottish Medicines Consortium Accepts Iluvien for Prevention of Relapse in Recurrent Noninfectious Uveitishttps://modernod.com/news/scottish-medicines-consortium-accepts-iluvien-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis/2478259/The Scottish Medicines Consortium (SMC) has accepted Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) for use within NHS Scotland for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS) in adults.1<
- Allergan, Sightsavers, and the IAPB Announce the “Keep Sight” Initiative to Address Glaucoma in Ganjam, Odishahttps://modernod.com/news/allergan-sightsavers-and-the-iapb-announce-the-keep-sight-initiative-to-address-glaucoma-in-ganjam-odisha/2477318/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) announced the launch of its unique joint initiative, ‘Keep Sight India,’ a community-based glaucoma screening program to prevent glaucoma-related vision loss in Ganjam District, Odisha. The pilot kicked off
- Santen Announces Scottish Medicines Consortium Approval of Verkazia for Severe Vernal Keratoconjunctivitishttps://modernod.com/news/santen-announces-scottish-medicines-consortium-approval-of-verkazia-for-severe-vernal-keratoconjunctivitis/2476148/Santen UK announced that the Scottish Medicines Consortium (SMC) has approved Verkazia eye drops emulsion containing 0.1% (1mg/ml) ciclosporin for use by NHS Scotland for the treatment of the rare disease, severe vernal keratoconjun
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Staar Surgical Celebrates 2 Million Lens Milestone for Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-2-million-lens-milestone-for-implantable-collamer-lens-icl/2480897/Staar Surgical announced that more than 2 million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses–EVO Visian ICLs (EVO). New to the U.S. market, E